Sanofi SA: Diferență între versiuni
Admin (discuție | contribuții) (csv2wiki) |
Admin (discuție | contribuții) (csv2wiki) |
||
Linia 2: | Linia 2: | ||
Pagina dedicata companiei Sanofi SA listata cu simbolul FR.SAN | Pagina dedicata companiei Sanofi SA listata cu simbolul FR.SAN | ||
==Grafic actiuni companie== | |||
<iframe key="tradeville" path="graficSimbol/FR.SAN"></iframe> | |||
==Descriere companie== | ==Descriere companie== | ||
Sanofi SA (www.sanofi.com) is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others. | Sanofi SA (www.sanofi.com) is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others. |
Versiunea de la data 22 septembrie 2023 10:46
Pagina dedicata companiei Sanofi SA listata cu simbolul FR.SAN
Grafic actiuni companie
Descriere companie
Sanofi SA (www.sanofi.com) is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
Ultimele stiri despre Sanofi SA (FR.SAN)
- Veniturile publice, in crestere - 28 octombrie 2024
- Rectificari bugetare - 23 septembrie 2024
- Un deficit comercial mai mic in T1 2023 - 13 mai 2024
- Terenurile agricole devin mai valoroase - 22 decembrie 2023
- PIB revizuit in crestere - 08 decembrie 2023
- Tendinte economice in T3 2023 - 31 iulie 2023
- Bancile cu capital romanesc si-au majorat cotele de piata - 30 iunie 2023
- Bancile inregistreaza profituri record in T1 2023 - 23 mai 2023
- Sanofi, mizand pe vanzarile Dupixent - 07 februarie 2023
- Sanofi, GSK variant-specific COVID shot found effective against Omicron - 24 iunie 2022